Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial.
Jamie P Dwyer, Noha Maklad, Ola Vedin...
https://pubmed.ncbi.nlm.nih.gov/40913594/Actively Recruiting
Led by AstraZeneca · Updated on 2026-10-21
11300
Participants Needed
977
Research Sites
N/A
Total Duration
Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.
CONDITIONS
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
A
AstraZeneca Clinical Study Information Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AstraZeneca
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Baxdrostat + dapagliflozin | Placebo + dapagliflozin | Dapagliflozin alone |
|---|---|---|---|
| What it is | An investigational oral combination of baxdrostat (an aldosterone synthase inhibitor) added to dapagliflozin | A placebo tablet added to dapagliflozin | Dapagliflozin alone as guideline‑recommended standard therapy to reduce risk of heart failure in type 2 diabetes with cardiovascular disease |
| Role in trial | Investigational treatment arm | Control arm receiving placebo plus dapagliflozin | Current standard preventive therapy not tested in this trial arm |
| Primary use | To test whether adding baxdrostat to dapagliflozin reduces heart failure events or cardiovascular death | To compare outcome with placebo when given alongside dapagliflozin | Current preventive treatment to reduce risk of heart failure in this patient group |
| How it is given or performed | Oral daily tablets: baxdrostat plus dapagliflozin | Oral daily tablets: placebo plus dapagliflozin | Oral daily dapagliflozin as per usual practice |
| Evidence status | Effectiveness for preventing heart failure events or CV death is being studied in this trial and not yet established | Control comparison to measure added value of baxdrostat | Well‑established efficacy for reducing heart failure risk and hospitalization in patients with type 2 diabetes and cardiovascular disease |
| Important limitations | Results are not yet available and applicability outside trial settings is unknown | Comparator reflects placebo plus dapagliflozin, which may not reflect usual care that includes dapagliflozin alone | Effectiveness derives from broader populations and may differ in this specific high‑risk cohort |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - Up to 14 days for screening, then 4 to 6 weeks for run-in if applicable
Participants are screened for eligibility, including consent and baseline assessments. Those not on or recently started on SGLT2 inhibitors enter a run-in period taking dapagliflozin for 4 to 6 weeks before randomization.
Visits as needed during screening and run-in periods
Duration - Up to about 38 months or until enough heart failure or cardiovascular events occur
Participants are randomly assigned to receive baxdrostat with dapagliflozin or placebo with dapagliflozin. Doses of baxdrostat may be increased if criteria are met. Study visits occur regularly to monitor health and collect data.
Visits at approximately 2, 4, 8, 16, and 34 weeks after randomization, then every 4 months
Duration - Until study closure after sufficient events have occurred
Participants who stop the blinded study treatment early may continue open-label dapagliflozin and will continue scheduled visits and data collection according to the study protocol.
Continued regular visits as per treatment stage
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jamie P Dwyer, Noha Maklad, Ola Vedin...
https://pubmed.ncbi.nlm.nih.gov/40913594/AstraZeneca
Lead Sponsor